A20 suppresses inflammatory responses and bone destruction in human fibroblast-like synoviocytes and in mice with collagen-induced arthritis

Arthritis and Rheumatism

Volumn 62, Issue 8, 2010, Pages 2313-2321

  Hah, Young Sool ^a   Lee, Young Rae ^b   Jun, Jin Su ^a   Lim, Hye Song ^a   Kim, Hyun Ok ^a   Jeong, Yong Geun ^a   Hur, Gang Min ^c   Lee, Sang Yong ^b   Chung, Myoung Ja ^b   Park, Jin Woo ^b   Lee, Sang Il ^a   Park, Byung Hyun ^b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIRHEUMATIC AGENT; BETA GALACTOSIDASE; CHEMOKINE; COMPLEMENTARY DNA; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MATRIX METALLOPROTEINASE; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN A20;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ARTICLE; BONE DESTRUCTION; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENZYME RELEASE; FIBROBLAST; FIBROBLAST LIKE SYNOVIOCYTE; HINDLIMB; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; JOINT RADIOGRAPHY; MALE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; THICKNESS;

ANALYSIS OF VARIANCE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; BONE AND BONES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED DBA; NF-KAPPA B; NUCLEAR PROTEINS; SYNOVIAL MEMBRANE;

EID: 77955409436     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27545     Document Type: Article

References (32)

1. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8.
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
3. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004;36:372-8.
4. Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM, et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 2004;50:3866-77.
5. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994;94:1012-8.
6. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor κB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1β-stimulated synovial fibroblasts. Arthritis Rheum 1998;41:1987-94.
7. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
8. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
9. Heyninck K, Beyaert R. A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends Biochem Sci 2005;30:1-4. (Pubitemid 40093732)
10. Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2003;2:550-2.
11. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009;284:8217-21.
12. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 2000;289:2350-4.
13. Orozco G, Hinks A, Eyre S, Ke X, Gibbons LJ, Bowes J, et al. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet 2009;18:2693-9.
14. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007;39:1477-82.
15. Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007;39:1431-3.
16. Liuwantara D, Elliot M, Smith MW, Yam AO, Walters SN, Marino E, et al. Nuclear factor-κB regulates β-cell death: a critical role for A20 in β-cell protection. Diabetes 2006;55:2491-501.
17. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, et al. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 2007;115:1885-94.
18. Kang NI, Yoon HY, Lee YR, Won M, Chung MJ, Park JW, et al. A20 attenuates allergic airway inflammation in mice. J Immunol 2009;183:1488-95.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Lee YR, Lee JH, Noh EM, Kim EK, Song MY, Jung WS, et al. Guggulsterone blocks IL-1β-mediated inflammatory responses by suppressing NF-κB activation in fibroblast-like synoviocytes. Life Sci 2008;82:1203-9.
21. Lee JH, Song MY, Song EK, Kim EK, Moon WS, Han MK, et al. Overexpression of SIRT1 protects pancreatic β-cells against cytokine toxicity by suppressing the nuclear factor-κB signaling pathway. Diabetes 2009;58:344-51.
22. Joosten LA, Helsen MM, Saxne T, van de Loo FA, Heinegard D, van den Berg WB. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999;163:5049-55.
23. Lee YR, Kweon SH, Kwon KB, Park JW, Yoon TR, Park BH. Inhibition of IL-1β-mediated inflammatory responses by the IκBα super-repressor in human fibroblast-like synoviocytes. Biochem Biophys Res Commun 2009;378:90-4.
24. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
25. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-45. (Pubitemid 30413866)
26. Canas CA, Tobon GJ, Arango LG, Guarin N. Developing of granulomatous thyroiditis during etanercept therapy. Clin Rheumatol 2009;28 Suppl 1:S17-9.
27. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004;430:694-9. (Pubitemid 39061687)
28. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc Natl Acad Sci U S A 1996;93:6721-5. (Pubitemid 26230376)
29. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004;5:1052-60. (Pubitemid 41057725)
30. Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKγ) upon receptor stimulation. Immunity 2000;12:301-11.
31. Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, et al. Transcription factor decoy for NFκB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (Oxford) 2000;39:749-57. (Pubitemid 30488507)
32. Cronstein BN. Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65 Suppl 1:S11-5.